SG11201705808XA - Glypican epitopes and uses thereof - Google Patents

Glypican epitopes and uses thereof

Info

Publication number
SG11201705808XA
SG11201705808XA SG11201705808XA SG11201705808XA SG11201705808XA SG 11201705808X A SG11201705808X A SG 11201705808XA SG 11201705808X A SG11201705808X A SG 11201705808XA SG 11201705808X A SG11201705808X A SG 11201705808XA SG 11201705808X A SG11201705808X A SG 11201705808XA
Authority
SG
Singapore
Prior art keywords
glypican
epitopes
glypican epitopes
Prior art date
Application number
SG11201705808XA
Inventor
Douglas Campbell
Fuenmayor Irene Justiniano
Aline Nocon
Julie Soon
Quach Truong
Bradley Walsh
Sandra Wissmueller
Original Assignee
Minomic Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minomic Int Ltd filed Critical Minomic Int Ltd
Publication of SG11201705808XA publication Critical patent/SG11201705808XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4722—Proteoglycans, e.g. aggreccan

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201705808XA 2015-01-16 2015-01-16 Glypican epitopes and uses thereof SG11201705808XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/AU2015/000019 WO2016112423A1 (en) 2015-01-16 2015-01-16 Glypican epitopes and uses thereof

Publications (1)

Publication Number Publication Date
SG11201705808XA true SG11201705808XA (en) 2017-08-30

Family

ID=56405046

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201705808XA SG11201705808XA (en) 2015-01-16 2015-01-16 Glypican epitopes and uses thereof

Country Status (11)

Country Link
US (2) US20180002391A1 (en)
EP (1) EP3245219B1 (en)
JP (1) JP6735005B2 (en)
KR (1) KR102435383B1 (en)
CN (1) CN107531755B (en)
AU (1) AU2015376851B2 (en)
CA (1) CA2973771A1 (en)
DK (1) DK3245219T3 (en)
ES (1) ES2805085T3 (en)
SG (1) SG11201705808XA (en)
WO (1) WO2016112423A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6749901B2 (en) * 2014-10-23 2020-09-02 グリピー ホールディングス ピーティーワイ リミテッド Monoclonal anti-GPC-1 antibody and uses thereof
JP7063623B2 (en) 2015-04-20 2022-05-09 グリザリックス リミテッド Therapeutic antibodies and their use
US20200308299A1 (en) * 2017-04-28 2020-10-01 National University Corporation Kochi University Anti-gpc-1 antibody
EP3883971A1 (en) * 2019-01-22 2021-09-29 The United States of America, as represented by the Secretary, Department of Health and Human Services High affinity monoclonal antibodies targeting glypican-1 and methods of use
CN111187350A (en) * 2019-12-30 2020-05-22 西安英创生物技术有限公司 Antigen binding protein combined with glypican-1
WO2024083921A1 (en) 2022-10-19 2024-04-25 Centro Di Riferimento Oncologico Di Aviano Anti-gpc1 monoclonal antibody, therapeutic and diagnostic uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356270A (en) 1977-11-08 1982-10-26 Genentech, Inc. Recombinant DNA cloning vehicle
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
WO1999037764A2 (en) * 1998-01-27 1999-07-29 Vlaams Interuniversitair Instituut Voor Biotechnologie New members of the glypican gene family
CA2346264A1 (en) * 1998-10-16 2000-04-27 Regents Of The University Of California Glypicans for the detection and treatment of human carcinoma
US20040226056A1 (en) * 1998-12-22 2004-11-11 Myriad Genetics, Incorporated Compositions and methods for treating neurological disorders and diseases
DE60228721D1 (en) * 2001-06-22 2008-10-16 Chugai Pharmaceutical Co Ltd Zellproliferationsinhibitoren mit anti-glypican-3-antikörper
ATE486610T1 (en) * 2004-07-09 2010-11-15 Chugai Pharmaceutical Co Ltd ANTI-GLYPICAN-3 ANTIBODIES
US20070087005A1 (en) * 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
WO2010019250A2 (en) 2008-08-11 2010-02-18 Solarflare Communications, Inc. Method of synchronization for low power idle
CN102180969B (en) * 2011-01-30 2013-04-10 中国人民解放军军事医学科学院微生物流行病研究所 Monoclonal antibody with liver cancer resisting activity and application thereof

Also Published As

Publication number Publication date
JP6735005B2 (en) 2020-08-05
CA2973771A1 (en) 2016-07-21
WO2016112423A1 (en) 2016-07-21
AU2015376851B2 (en) 2020-07-09
EP3245219A4 (en) 2018-06-06
KR20170109584A (en) 2017-09-29
JP2018504903A (en) 2018-02-22
ES2805085T3 (en) 2021-02-10
DK3245219T3 (en) 2020-06-29
EP3245219A1 (en) 2017-11-22
US20210107958A1 (en) 2021-04-15
CN107531755A (en) 2018-01-02
CN107531755B (en) 2022-02-25
US20180002391A1 (en) 2018-01-04
EP3245219B1 (en) 2020-04-08
KR102435383B1 (en) 2022-08-24
AU2015376851A1 (en) 2017-07-27

Similar Documents

Publication Publication Date Title
IL283321A (en) Anti-muc16 antibodies and uses thereof
IL285375A (en) Il-8-binding antibodies and uses thereof
HK1254861A1 (en) Anti-lag3 antibodies and uses thereof
IL258248A (en) Affinity-oligonucleotide conjugates and uses thereof
HK1250238A1 (en) Anti-angptl8 antibodies and uses thereof
HK1255067A1 (en) Anti-c10orf54 antibodies and uses thereof
HK1243440A1 (en) Anti-interleukin-33 antibodies and uses thereof
IL247407B (en) Anti-egfrviii antibodies and uses thereof
HK1256381A1 (en) Anti-pacap antibodies and uses thereof
GB201503387D0 (en) Anti-carbapenem antibodies and uses thereof
IL251001B (en) Anti-il-25 antibodies and uses thereof
RS62912B1 (en) Anti-human-her3 antibodies and uses thereof
SG11201705808XA (en) Glypican epitopes and uses thereof
HK1247122A1 (en) Combinations and uses thereof
IL254241A0 (en) Etv2 and uses thereof
HK1254240A1 (en) Anti-hypusine antibodies and uses thereof
AU2016041V (en) Primaris Diplotaxis tenuifolia
HK1202024A2 (en) Umbrella shape direction valve